Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) reported earnings per share of $0.07


Dallas, Texas 11/18/2013 (Financialstrend) – Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) issued its quarterly-earnings report on Thursday. It reported an earnings per share of 0.07 for the quarter which was on par with the average analyst estimate of $0.07.

Recently, numerous research firms have weighed on the Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) stock. Aegis’s analysts have upped their PT on Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) shares from $4.00 to $5.50  on 21 October and have now set a “buy” rating on the company stock. Zacks analysts upgraded Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) shares from a  “neutral” to an “outperform” rating on 18 October and have now set a PT of $3.10 on the stock.

Friday’s trading

In Friday’s trading session, Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) rose by 13.48%. The shares opened at a price of $1.43, which touched the intraday high of $1.65 and headed to a close of $1.60. Around 1.46 million exchanged hands over the trading day and an average volume of 2.30 million shares were traded over a 30 day period. The 52-week low of Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX)  shares is $0.40 and its 52-week high is $3.65. The company has a market capitalization of $84.63 million.

About the company

Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage bio- pharmaceutical company. It focuses  on developing & commercializing prescription drugs that target addiction diseases & disorders of the central-nervous system with a primary focus on treatment of addiction &epilepsy. As of 31 December 2011, it had 2drugs in development: CPP-109 & CPP-115. As of 31 December 2011, Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) was evaluating the company’s drug candidate, CPP-109 in the treatment of cocaine-addiction. As of 31 December 2011, it was in the earl-stages of developing CPP-115. This is one more GABA aminotransferase-inhibitor. It has identified 2 market-opportunities that can be exploited by pharmacotherapies. These  inhibit GABA-aminotransferase (GABA-AT): drug addiction & epilepsy.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.